Prolongation of the QTc interval predicts appropriate implantable cardioverter-defibrillator therapies in hypertrophic cardiomyopathy

JACC: Heart Failure

Volumn 1, Issue 2, 2013, Pages 149-155

  Gray, Belinda ^a,b   Ingles, Jodie ^b,c   Medi, Caroline ^a,c   Semsarian, Christopher ^a,b,c  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c CENTENARY INSTITUTE   (Australia)

Author keywords

Clinical predictor; Hypertrophic cardiomyopathy; Implantable cardioverter defibrillator; QT interval

Indexed keywords

ADULT; ARTICLE; AUSTRALIA; CONTROLLED STUDY; DISEASE ASSOCIATION; ELECTROCARDIOGRAM; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PATIENT SELECTION; PREDICTION; PRIORITY JOURNAL; QT PROLONGATION; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SUDDEN CARDIAC DEATH; SURVIVAL RATE; TREATMENT DURATION;

CLINICAL PREDICTOR; HYPERTROPHIC CARDIOMYOPATHY; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; QT INTERVAL;

ADULT; CARDIOMYOPATHY, HYPERTROPHIC; DEFIBRILLATORS, IMPLANTABLE; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; PREDICTIVE VALUE OF TESTS; TIME FACTORS;

EID: 84877949079     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2013.01.004     Document Type: Article

References (31)

1. Lind J.M., Chiu C., Semsarian C. Genetic basis of hypertrophic cardiomyopathy. Expert Rev Cardiovasc Ther 2006, 4:927-934.
2. Marian A.J. Hypertrophic cardiomyopathy: from genetics to treatment. Eur J Clin Invest 2010, 40:360-369.
3. Maron B.J., Maron M.S., Semsarian C. Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives. J Am Coll Cardiol 2012, 60:705-715.
4. Maron B.J., Gardin J.M., Flack J.M., Gidding S.S., Kurosaki T.T., Bild D.E. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA (Coronary Artery Risk Development in [Young] Adults) Study. Circulation 1995, 92:785-789.
5. Watkins H., Ashrafian H., Redwood C. Inherited cardiomyopathies. N Engl J Med 2011, 364:1643-1656.
6. Seidman J.G., Seidman C. The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell 2001, 104:557-567.
7. Maron B.J. Sudden death in young athletes. N Engl J Med 2003, 349:1064-1075.
8. Maron B.J., Spirito P., Shen W.K., et al. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA 2007, 298:408-412.
9. Schinkel AF, Vriesendorp PA, Sijbrands EJ, Jordaens LJ, Ten Cate FJ, Michels M. Outcome and complications after implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy: systematic review and meta-analysis. 2012;5:552-9.
10. Jayatilleke I., Doolan A., Ingles J., et al. Long-term follow-up of implantable cardioverter defibrillator therapy for hypertrophic cardiomyopathy. Am J Cardiol 2004, 93:1192-1194.
11. Maron B.J. Risk stratification and role of implantable defibrillators for prevention of sudden death in patients with hypertrophic cardiomyopathy. Circ J 2010, 74:2271-2282.
12. Gersh B.J., Maron B.J., Bonow R.O., et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy. J Am Coll Cardiol 2011, 58:e212-e260.
13. Maron B.J., Maron M.S., Semsarian C. Double or compound sarcomere mutations in hypertrophic cardiomyopathy: a potential link to sudden death in the absence of conventional risk factors. Heart Rhythm 2012, 9:57-63.
14. Begley D.A., Mohiddin S.A., Tripodi D., Winkler J.B., Fananapazir L. Efficacy of implantable cardioverter defibrillator therapy for primary and secondary prevention of sudden cardiac death in hypertrophic cardiomyopathy. Pacing Clin Electrophysiol 2003, 26:1887-1896.
15. Goldenberg I., Moss A.J., Peterson D.R., et al. Risk factors for aborted cardiac arrest and sudden cardiac death in children with the congenital long-QT syndrome. Circulation 2008, 117:2184-2191.
16. Hobbs J.B., Peterson D.R., Moss A.J., et al. Risk of aborted cardiac arrest or sudden cardiac death during adolescence in the long-QT syndrome. JAMA 2006, 296:1249-1254.
17. Sauer A.J., Moss A.J., McNitt S., et al. Long QT syndrome in adults. J Am Coll Cardiol 2007, 49:329-337.
18. Johnson J.N., Grifoni C., Bos J.M., et al. Prevalence and clinical correlates of QT prolongation in patients with hypertrophic cardiomyopathy. Eur Heart J 2011, 32:1114-1120.
19. Jouven X., Hagege A., Charron P., et al. Relation between QT duration and maximal wall thickness in familial hypertrophic cardiomyopathy. Heart 2002, 88:153-157.
20. Martin A.B., Garson A., Perry J.C. Prolonged QT interval in hypertrophic and dilated cardiomyopathy in children. Am Heart J 1994, 127:64-70.
21. Uchiyama K., Hayashi K., Fujino N., et al. Impact of QT variables on clinical outcome of genotyped hypertrophic cardiomyopathy. Ann Noninvasive Electrocardiol 2009, 14:65-71.
22. Maron B.J., Leyhe M.J., Casey S.A., et al. Assessment of QT dispersion as a prognostic marker for sudden death in a regional nonreferred hypertrophic cardiomyopathy cohort. Am J Cardiol 2001, 87:114-115. [abstract 9].
23. Delcre S.D., Di Donna P., Leuzzi S., et al. Relationship of ECG findings to phenotypic expression in patients with hypertrophic cardiomyopathy: a cardiac magnetic resonance study. Int J Cardiol 2012; Mar 29, [Epub ahead of print].
24. Dritsas A., Sbarouni E., Gilligan D., Nihoyannopoulos P., Oakley C.M. QT-interval abnormalities in hypertrophic cardiomyopathy. Clin Cardiol 1992, 15:739-742.
25. Sen-Chowdhry S., McKenna W.J. Sudden death from genetic and acquired cardiomyopathies. Circulation 2012, 125:1563-1576.
26. Moss A.J. Long QT syndrome. JAMA 2003, 289:2041-2044.
27. Ackerman M.J., Priori S.G., Willems S., et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies. This document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Heart Rhythm 2011, 8:1308-1339.
28. Kapplinger J.D., Tester D.J., Alders M., et al. An international compendium of mutations in the SCN5A-encoded cardiac sodium channel in patients referred for Brugada syndrome genetic testing. Heart Rhythm 2010, 7:33-46.
29. Gosselin-Badaroudine P., Keller D.I., Huang H., et al. A proton leak current through the cardiac sodium channel is linked to mixed arrhythmia and the dilated cardiomyopathy phenotype. PLoS One 2012, 7:e38331.
30. Kapplinger J.D., Tester D.J., Salisbury B.A., et al. Spectrum and prevalence of mutations from the first 2,500 consecutive unrelated patients referred for the FAMILION long QT syndrome genetic test. Heart Rhythm 2009, 6:1297-1303.
31. Kelly M., Semsarian C. Multiple mutations in genetic cardiovascular disease: a marker of disease severity?. Circ Cardiovasc Genet 2009, 2:182-190.